MCY-M11

MCY-M11 is an investigational, non-viral, mRNA-based chimeric antigen receptor (CAR) cell therapy designed to target mesothelin-expressing solid tumors. The therapy is manufactured by transfecting autologous peripheral blood mononuclear cells (PBMCs) with mRNA encoding a human anti-mesothelin CAR using flow electroporation technology. This process enables rapid (<1 day) manufacturing of the cell product without the need for preconditioning chemotherapy[5][6]. Upon administration, MCY-M11 stimulates the immune system to induce a cytotoxic T-lymphocyte response against cancer cells that overexpress mesothelin—a glycoprotein involved in cell adhesion and commonly found on many epithelial-derived cancers such as ovarian cancer, fallopian tube cancer, and peritoneal mesothelioma[1][3]. The product contains a mix of immune cells including T cells (CD4+ and CD8+), NK cells, B cells, and monocytes that exhibit activation markers and secrete immunostimulatory molecules to mount an extended antitumor response[7]. Developed using MaxCyte’s proprietary CARMA platform in collaboration with Sidney Kimmel Comprehensive Cancer Center, MCY-M11 is currently being evaluated in Phase I clinical trials for relapsed/refractory ovarian cancer and peritoneal mesothelioma[3][4][6].

Other names

autologous mesothelin-specific human mRNA CAR-transfected PBMCs